Radiotheranostics Market Size, Share & Trend Analysis Report By Radioisotope (Iodine-131, Gallium-68, Lutetium-177, 18F with Y-90), By Approach (Therapeutic, Diagnostic), By Application, By Region, and Segment Forecasts, 2023 To 2030

Radiotheranostics refers to the use of radioisotopes for paired imaging and therapeutic purposes. It is a methodical combination of tailored diagnostics and therapeutics. The rising prevalence of cancer and the increasing use of injectable radiopharmaceuticals with antitumor effects are driving the global radiotheranostics market. These agents improves therapy efficacy and the ability to handle adverse & critical health situations, resulting in better patient outcomes. Furthermore, the growing use in cancer detection and treatment is propelling the industry forward.

Furthermore, new research & developments initiatives are expected to have a positive impact on the market growth. For instance, there have been significant breakthroughs in the market for prostate cancer as well as neuroendocrine tumours. Moreover, the regulatory approval of a number of radiotheranostics pairs is anticipated to increase their use in cancer treatments. For example, the approval of new agents including 177Lu-PSMA-617 & 177Lu-DOTATATE has resulted in a resurgence of radiotheranostics study and has increased the number of clinical trials and testing of several other novel agents. Furthermore, continuous support in R&D to keep up with the present momentum in advancements is assisting regional expansion. 

Additionally, the therapeutic use of these agents has increased significantly as a result of effective advances in understanding the underlying biology of cancer and improved methods for synthesizing and designing specific theragnostic agents. This, in turn, has a favorable impact on market growth.

Radiotheranostics Market Segmentation

Key companies operating in the radiotheranostics market include Novartis AG; GE Healthcare Inc; Lantheus Medical Imaging; Jubilant Pharma Limited; Radiopharm Theranostics; Curium SAS; Bayer AG; Sirtex Medical Limited; Nordic Nanovector ASA; and Actinium

Pharmaceuticals, Inc. amongst others.